Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Chimera Antigen Receptor (CAR)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT07135466
What this trial is testing

T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies

Who this might be right for
B Cell Malignancies
Sheba Medical Center 50
Early research (Phase 1)Looking for participantsNCT06892145
What this trial is testing

Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE

Who this might be right for
Systemic Lupus Erythematosus (SLE)Refractory
Chongqing Precision Biotech Co., Ltd 12
Early research (Phase 1)UnknownNCT03018093
What this trial is testing

A Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+B-ALL

Who this might be right for
Relapsed or Refractory Acute Lymphoblastic Leukemia
Shanghai AbelZeta Ltd. 20
Early research (Phase 1)Active Not RecruitingNCT04219163
What this trial is testing

Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen

Who this might be right for
Acute Myeloid Leukemia
Baylor College of Medicine 18
Testing effectiveness (Phase 2)Active Not RecruitingNCT04133636
What this trial is testing

JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 208
Early research (Phase 1)UnknownNCT03298828
What this trial is testing

CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma

Who this might be right for
Acute Lymphoblastic LeukemiaBurkitt Lymphoma
Third Military Medical University 30
Testing effectiveness (Phase 2)Looking for participantsNCT06585514
What this trial is testing

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus

Who this might be right for
Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)
Beijing GoBroad Hospital 18
Not applicableLooking for participantsNCT05988216
What this trial is testing

Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus Erythematosus

Who this might be right for
Systemic Lupus Erythematosus (SLE)
Bioray Laboratories 12
Early research (Phase 1)Study completedNCT03448393
What this trial is testing

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Who this might be right for
Lymphoma, Non-HodgkinLeukemia, Lymphocytic, B CellB-Cell Lymphoma+7 more
National Cancer Institute (NCI) 54
Very early researchNot Yet RecruitingNCT06196658
What this trial is testing

Early Phase I Study of Autologous T Cells (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer

Who this might be right for
Pancreatic CancerAdvanced Biliary Cancer
Zhang Xiaofeng,MD 6
Testing effectiveness (Phase 2)UnknownNCT03262298
What this trial is testing

Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies

Who this might be right for
LeukemiaLymphoma
Affiliated Hospital to Academy of Military Medical Sciences 20
Testing effectiveness (Phase 2)Study completedNCT04325841
What this trial is testing

Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children

Who this might be right for
Acute Lymphoblastic Leukemia, PediatricAcute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic Leukemia
Beijing Boren Hospital 2
Early research (Phase 1)Looking for participantsNCT06408194
What this trial is testing

Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

Who this might be right for
LeukemiaAcute Lymphoblastic Leukemia
Stanford University 28
Early research (Phase 1)UnknownNCT03716856
What this trial is testing

Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma

Who this might be right for
Refractory or Relapsed Multiple Myeloma
First Affiliated Hospital of Zhejiang University 11
Not applicableNot Yet RecruitingNCT06890091
What this trial is testing

Study of the Association Between Fatigue Experienced by Patients and the Specific Side Effects of CART Cells, During the First Month After Administration for Non-Hodgkin's Lymphoma

Who this might be right for
Fatigue SymptomLymphoma Non-HodgkinChimeric Antigen Receptor T-cell Therapy+1 more
Assistance Publique - Hôpitaux de Paris 100
Testing effectiveness (Phase 2)Study completedNCT03483103
What this trial is testing

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)

Who this might be right for
Lymphoma, Non-HodgkinLymphoma, NonhodgkinLymphoma, B-Cell+1 more
Juno Therapeutics, a Subsidiary of Celgene 74
Testing effectiveness (Phase 2)Active Not RecruitingNCT05736731
What this trial is testing

Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

Who this might be right for
Solid Tumor, AdultSolid TumorPancreatic Cancer+13 more
A2 Biotherapeutics Inc. 160
Very early researchLooking for participantsNCT05620342
What this trial is testing

Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

Who this might be right for
Lung CancerSmall Cell Lung CarcinomaNon Small Cell Lung Cancer
UNC Lineberger Comprehensive Cancer Center 24
Early research (Phase 1)Enrolling By InvitationNCT07168486
What this trial is testing

CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas

Who this might be right for
B-Cell LymphomaDiffuse Large B Cell Lymphoma (DLBCL)Primary Mediastinal Large B-cell Lymphoma (PMBCL)+7 more
University of Maryland, Baltimore 15
Testing effectiveness (Phase 2)Looking for participantsNCT06479356
What this trial is testing

CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma

Who this might be right for
Non-Hodgkin LymphomaLarge B-cell Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd. 12
Next Page